Revance Therapeutics reported $25.26M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US $ 13538M 1348M
Aerie Pharmaceuticals AERI:US $ 29.84M 84.83M
ALKERMES ALKS:US $ 278.54M 45.92M
Bristol Myers Squibb BMY:US $ 11648M 337M
Cara Therapeutics CARA:US $ 4.79M 3.97M
Coherus Biosciences CHRS:US $ 60.12M 13.26M
Eli Lilly And LLY:US $ 7810M 189.9M
Endo International Ordinary Shares ENDP:US $ 652.26M 137.17M
Horizon Pharma HZNP:US $ 885.24M 129.22M
JAZZ PHA JAZZ:US $ 813.72M 83.01M
Johnson & Johnson JNJ:US $ 23426M 1378M
Merk MRK:US $ 15901M 2380M
Neurocrine Biosciences NBIX:US $ 310.6M 1.4M
Pacira Pharmaceuticals PCRX:US $ 157.99M 1.2M
Procter & Gamble PG:US $ 19381M 1572M
Revance Therapeutics RVNC:US $ 25.26M 0.69M
Supernus Pharmaceuticals SUPN:US $ 152.51M 6.54M
Teva Pharmaceutical Industries TEVA:US $ 3661M 439M